Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity

This study has been completed.
Information provided by:
Università degli Studi dell'Insubria Identifier:
First received: March 27, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted
Despite the great number of reports about the efficacy of oestrogens or antimuscarinics on OAB symptoms, so far no author has tried to investigate whether the concomitant administration of these two drugs, acting on two different pathophysiological mechanisms, could have a synergic effect reducing the rate of non-responders to treatment.

Condition Intervention Phase
Overactive Bladder
Drug: Tolterodine 4 mg
Drug: arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
Phase 2
Phase 3

Study Type: Interventional
Official Title: Is There A Synergic Effect Of Topical Oestrogens When Associated To Antimuscarinics In The Treatment Of Symptomatic Detrusor Overactivity

Resource links provided by NLM:

Further study details as provided by Università degli Studi dell'Insubria:

Study Start Date: January 2004
Study Completion Date: December 2007
Arms Assigned Interventions
Active Comparator: 1
arm 1: Tolterodine 4 mg once daily for 12 weeks
Drug: Tolterodine 4 mg
Experimental: 2
arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
Drug: arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All post-menopausal women with symptoms of overactive bladder and urodynamically proven pure detrusor overactivity

Exclusion Criteria:

  • concomitant urodynamic stress incontinence
  • documented recurrent urinary tract infections
  • previous antimuscarinic treatment
  • previous pelvic surgery
  • concomitant systemic HRT
  • history of breast or endometrial cancer
  • neurological disease
  • clinical contraindications to treatment with oestrogen or antimuscarinics
  • patients included in other ongoing clinical trials
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00648310

Department of Gynecology and Obstetrics - Università dell'Insubria
Varese, Italy, 21100
Sponsors and Collaborators
Università degli Studi dell'Insubria
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00648310     History of Changes
Other Study ID Numbers: local oestrogens 9/2003
Study First Received: March 27, 2008
Last Updated: March 27, 2008

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Muscarinic Antagonists
Tolterodine Tartrate
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on May 24, 2017